VKTX - Earnings call transcript Q1 2019 | Viking Therapeutics, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good day, and welcome to the Viking Therapeutics First Quarter 2019 Earnings Conference Call and Webcast. All participants will be in a listen-only mode. [Operator Instructions] After today's presentation, there will be an opportunity to ask questions. [Operator Instructions] Please note this event is being recorded. I would like to now turn the conference over to Stephanie Diaz, Investor Relations. ahead. go Please

Stephanie Diaz

you thank participating today's in Hello, all call. and for

is Joining of President Brian and today Finance CEO; Administration. President Viking's Vice Lian, me Morneau, and and Michael

results these during like will the XXXX forward-looking company, differ the or undertakes you beliefs number of the statements could for obligation of update over other a the that begin, XXXX May Securities meaning no any contain to of the all Brian? which and and Securities comments. we call, I'll encourage today, initial involve these the I'd company's matters. review comments call statements to I Before uncertainties. assumptions, and now company of Brian made the this and within concerning conference X, concerning the to current Actual Exchange caution filings with from Lian statement risks, revise Act made to the Commission of today. turn

Brian Lian

everyone update on our webcast results, and progress first Thanks, programs Stephanie, overview well provide listening our developments related the and phone. recent and operations. an or as Today quarter as of financial pipeline an we'll on to to thanks by

hypercholesterolemia Phase and from promising muscle two best-in-class continued data further validated XXXX, fatty reported of XXXX, momentum XXXX molecules hip and VKXXXX of new bone During VKXXXX the as trial potency reported and our disease, have fracture. in Viking clinical following VKXXXX, programs liver for for safety. and the data we of from and X stimulation which The success

poster similar presented results results arms the XX showed EASL in evaluating in of reported at the dosing breaking that exposure higher at conference lower a last per to previously. data milligrams observed doses day, VKXXXX presented We late in latest recently that Specifically, efficacy Vienna. month these that is milligram this X

first, to detail I'll quarter VKXXXX, our Xb with in to to clinical NASH. I'll of financial study call the be over Morneau, trial for we'd further currently which next Mike? provide Mike biopsy-confirmed Vice financial But minutes. Administration with are review We President patients results. like in results. preparing our and first Viking's will discuss a our now turn few Finance a Phase

Michael Morneau

In Viking's comments, participants quarter for now additional filing Securities that and with conjunction to today Commission, I'll XX, Thanks, financial XXXX. expect later the I'd like with first over refer Brian. to my go March results for XX-Q recommend Exchange the which we to file details. ended the

$X.X million third-party study clinical and to XXXX. benefits, development drug was Our our for were a by partially for months salaries to study consultants, efforts, expenses. compared three to compensation in XXXX, stock-based use same expenses of research period the $X related manufacturing March expenses and primarily offset million the decrease pre-clinical in increased and XX, due ended candidates, increase The

third-party Our XX, were consultants. of administrative million to three million salaries The compensation, to for $X.X and increase XXXX. general period expenses same use related and and increased expenses compared primarily stock-based due XXXX the was months in benefits, for ended $X.X March the to

net XXXX. $X.X months three loss interest net increase XX, to general a $X.X and March loss three net the net offset and For of basic in Viking the months million and development company's XX, of in in well per compared debt increase as a in of research The of in due due was XXXX. as of million the ended net amortization a primarily a to $X.XX, decrease outstanding by change outstanding of The period increase in corresponding in administrative the the loss at expenses reported primarily ended XX, versus May to March in the XXXX per share XXXX, loss elimination per June public at March basic in offerings. fair to discount income XX, March an months XXXX, those net noted is share the XX, the issued share XXXX conversion for $X.XX through for equity the and three and ended additional of and the of previously, and liability, XXXX additional September loss shares the company the shares due by debt March value the XXXX, feature loss debt given repayment

$XXX.X cash equivalents sheet balance XXXX Our March XX, totaling million. and at cash, showed investments

to turn April over of outstanding. common XXth, of Viking This call I'll XXXX, stock my XX,XXX,XXX the had As and shares now concludes Brian. back review, financial

Brian Lian

we the stage Mike. which clinical programs, from was positive disease liver the XXXX, Phase VKXXXX result for of the build continued momentum growth. data upon to two VKXXXX our Thanks and first quarter, muscle for In gained in X

As were non-alcoholic with in including a small conference. VKXXXX lipid a endpoints, as liver Phase reductions liver in the NASH. plasma in potent in from and content of and for In we trial the tissue demonstrating an that lipid range results X potential November disease. promising orally late-breaker hypercholesterolemia September its The during and secondary reminder, year, fatty a is improvements the agonist hormone primary disorders, molecule AASLD the receptor trial steatohepatitis beta thyroid of positive available and oral measures. at suggesting subtype, These patients presented last of VKXXXX selectivity possesses achieved therapeutic liver of receptor or both as results announced fat well

daily, receive presented patients Association the last European primary milligrams trial's of VKXXXX Additional weeks after milligrams annual Phase late-breaking the trial of of evaluated a X VKXXXX or LDL on cholesterol to or meeting The compared in day XX were the endpoint poster the weeks. XX month doses This the placebo. effect at XX placebo every other Study Liver EASL. of for for randomize dosing results of XX to updated daily, milligrams X

change fat evaluated endpoint fraction assessed as by or proton secondary fat MRI liver The MRI-PDFF. in density

to LDL with reductions treated placebo respect EASL As the with patients. both the trial's endpoint, achieve significant patients at conferences, treated primary we compared in reported VKXXXX and statistically AASLD

treated lipoprotein to respect addition, experienced experienced significant of liver The VKXXXX the the apolipoprotein reductions endpoint, oral lipids, magnitude today. agents unprecedented by remains key other development this response and as statistically secondary including patients With improvements and in triglycerides MRI-PDFF. A. significant patients B VKXXXX among of fat treated atherogenic proteins, In assessed and

included a treated Approximately liver events XX% among rate fat treated a tolerability relative patients at milligrams from XX day of of in study. in with content receiving cohorts. fat an relative doses content. In reported or were at responder content. reduction placebo The VKXXXX NT-proBNP X%. dose were XX%. liver of VKXXXX XX% this reduction daily signs VKXXXX receiving demonstrated clinical this with of adverse XX responder serious experienced receiving study, other Specifically, odds placebo, least XX% the if patients was numbers every at when milligrams milligrams approximately doses experienced liver and reduction intended liver Mean liver and relatively baseline. VKXXXX similar were is or of to threshold relative as troponin, were reduction VKXXXX VKXXXX VKXXXX reduction more, of dosed Across Patients ALT content XX% were AST at a XX% experienced XX liver in X in distributed experienced per compared also placebo, as characterized in a median multiple have to XX% demonstrated for receiving they liver observed. content. were receiving vital across evenly observed XX% also toxicity reduction other of this patients those fat dosed the and of liver The patients treatment trial may receiving the there fat XX% the study. among from patients liver at milligrams a dose CV in day corresponding VKXXXX treated approximately markers CK-MB predict of all is to This experienced and a day, treated observed events approximately XX% with or a cardiovascular liver response. approximately median from arms. of VKXXXX cohorts, by demonstrated median By study reduction levels No relative baseline. And, VKXXXX in among across liver clinically XX among all between encouraging VKXXXX safety reduced fat XX demonstrated also a fat benefit. comparison, which overall also other broader between experienced By of weeks whether patients approximately treated differences XX%. patients relative XX% and fat in increase at in encouraging XX% No was a and fat fat daily was patients experienced in all VKXXXX test reduction and at interest assess improved patients as at this in receiving approximately or in receiving adverse were a VKXXXX changes milligrams meaningful relative responders, in content. with AEs median of the milligrams demonstrated overall patients in no least every placebo placebo, Patients placebo liver analysis, or fat fat daily, also profile baseline, VKXXXX reduction histology is such comparison, patients reduced patients least studies safety reduction related receiving numerically or placebo. cohorts function median approximately that least approximately X cardiovascular

compared of liver lipids dose tolerated with the shown maintained reductions is this atherogenic differences that of pleased as efficacy improve cardiovascular to characteristics adverse and while in events particular, its in robust the excited was in daily proteins. milligram distinguishing benefits health we're we're the dose, the and were Perhaps such with potential gastrointestinal profile VKXXXX VKXXXX through there and was at systemic well most to placebo. Overall, overall demonstrated study. related was in which no very one VKXXXX be study, providing of lowest LDL global the Finally, such X study,

we biopsy-confirmed to in we pre-IND meeting a Given requested the study at date and Phase meeting quarter, are VKXXXX a NASH. the In timeframe. FDA, in were with initiate preparing the a currently with first IIb granted these results, midsummer encouraging patients

Following this study. to to IND meeting, the an plan we initiate file

number While as FX anticipate have we trial been limited finalized, with and as fibrosis. details FX fibrosis FX with well a target study not patients design the regarding will

more the study XX months than up of dose to VKXXXX of dosing. one evaluate expect to for We

on a as X-ALD defect move devastating in now closer adrenoleukodystrophy will treatment agonists disease a X-ALD. the or update that further are as molecule VKXXXX provide an I'll receptor we to is evaluating provide X-linked peroxisomal about initiation. a We for ABCDX. is transporter we by thyroid information our small VKXXXX program. study caused a potential a called

this stimulate fatty small in acids study are evaluating beta our hallmarks Like of fatty effects plasma possesses defect, As Krieger is both that collaborators at very agonist receptor of X-ALD. for a The of this long acids, toxicities elevations, notably the VKXXXX, long-chain the Early leading that the to subtype. model a fatty XX-week cerebral in in contribute in may motor chain disease. severe a a on XXXX, patients an an to the study very chain setting. and tissue. receptor the disease, improvement of levels markers data VKXXXX of orally of tissue, VKXXXX have molecule and very activation sustained show beta plasma In the in early benefit which result Kennedy potentially are experience and completed metabolism available demonstrated thyroid promising selectivity animal and acid long results receptor therapeutic thyroid Institute, late a to the we neuron that believed an

and later IND conducting plan We to enabling proof-of-concept initiate file to in are this a this an currently study program work IND humans. year for

this advancing We pharmacological clinic We our have VKXXXX this first look excited disease. may that later are IND into as forward for offer to very year. debilitating be demonstrated this program the to data-to-date filing the treatment

through our multiple robust as provides sheet Mike to of the Finally, judicious runway fortune we which capital, coupled earlier, on clinical described with see inflection to corporate balance points. a sufficient use side have us maintain been

XXXX grateful are forward we from investors you XXXX. keeping to updated into look first the We our has from of and progresses. In pleased momentum as the for continued our are that pipeline success support quarter conclusion, our and

maintained targeting the safety data month, historical supports when dose programs improved unique with and observed EASL X X milligram doses belief to milligrams. VKXXXX, our provides trial robust, half that essentially reported to relative targeting that liver VKXXXX's in This exceptional benefit-to-risk profile this New receptor. XX tissue-specific demonstrated of at potency will in our from which the previously both mechanism the finding last profile effects Phase cutting were potentially

and and IND NASH Importantly, and significant the lipoprotein-a, VKXXXX cholesterol, biopsy-confirmed indicates atherogenic in long-term Xb on apolipoprotein-b We potential study track Phase LDL triglycerides, a benefit. treated which for in year. remain experienced cardiovascular proteins, to VKXXXX an reductions later statistically this patients file also initiate

We call to this comments our for of clinic Operator? for of This move concludes an now progress to plan to work half required us into for joining for IND program to continue XXXX. pre-IND our in X-ALD. I'd also the Thanks make questions. with VKXXXX the file second prepared We like the open the the program again and for today. treatment

Operator

you. Thank

will from Robinson with [Operator Edward comes Nash session. Please question begin now today We Instructions] question-and-answer the ahead. first go The SunTrust Humphrey.

Fang-Ke Huang

our This for much on taking so question. Edward is Fang-Ke you for Thank Nash.

see Phase kind we that rate the high can with and that the the you in so to have a first placebo X/X arm Phase understand trial, ancient trial, of I want continuing this the is The what's a reason mental follow-up. is I Xb? combination for is control relatively just And how is and -- which question XXXX for

Brian Lian

Yeah, Phase safety. study at X the to say, -- clinic IIa stays Holter in Fang-Ke for had They study as to the well hour extended a multiple for patients. telemetry come question. would burdensome I fairly just for cardiovascular as for for visits trial monitors measure for thanks Yeah, the was,

imposed those that some We the that to with expect upcoming be people events required. of So time the and the study. sort resulted schedule on in burdens not fatigued getting just do commitment was

So we lower that study. would in upcoming discontinuation the is rate the hope

more arms. to the think of relative highest I component the I is consider that the think important of was discontinuations the discontinuations to actually rate placebo treatment in

think help VKXXXX. should address receiving I about so, And safety associated any misperceptions with tolerability that and

Fang-Ke Huang

XXX. That's And the is very one on helpful. Great. second

mentioned CXX long your in chain CXX. So you to influence corporate presentation, different acid April fatty

which there to important are And long we chain want fatty any than when more Just And understand, these in different other? terms to of the acid. secondly, differences is toxicity between is one potential be update any do are trying Do chain on like have these the of long going of impatience you toxin fatty therapeutic understand benefit, that? goes important. acid have what's we out what different to then

Brian Lian

Yeah, questions. yeah, key are thanks. These

fatty is The So the also the shorter of in shorter CXX produced have The reason toxic, an most the amount elongation most that on when of as long it's long to carbon as acids the the or through important chains is robust and not they're toxic chain fatty to CXX fatty are the CXX. the process. very very and a two acids important chains are the that comes chain great we toxicity elongated it acid. CXX a interest chain note effect that are but

CXX. to compared So compared CXX CXX is CXX is to compared to is

as overall CXX. benefit. over It chain as provide the is So to of how heard well when and time, required reduce not disease. acid, interested from I CXX is and long That's versus CXX the you pool long reductions production important that chain is known how presumably it's known you exposure X% the We've great questions think this reduction the not one shorter deplete in of systemic of to key the also chain acids, XX% everybody plasma for fatty estimates fatty and various clinical are. tissue a anywhere

and tissue and effects plasma show in we Fortunately, in a CNS.

again, benefit but we until little determine able we thanks be for the clinical along, won't to -- a So but get questions. further real

Fang-Ke Huang

much. Great. you Thank so

Operator

go Our ahead. Steve with comes from James. next Seedhouse Please question Raymond

Timur Ivannikov

rodent on HP studies. the Ivannikov does over, tested And milligram Yes, VKXXXX let's GLP-toxicity ongoing doses about or first milligrams give What X.X five today. daily in the our say, coverage in hi. This is dose once you the human? is being Steve for today top Seedhouse Timur in question for

Michael Morneau

GLP so sufficient, on talks would we disclosed the the margins I details details. say haven't should disclosed Yeah, be the we dosing exposure studies. haven't but in those

Timur Ivannikov

study of about XX maybe milligram the arms, and regarding is question milligram magnitude talk in Phase and five the that the the maybe in the the that with you dose? bump question ALT, correlate bump about -- magnitude initial could and Okay, versus And okay. of another IIa bump Thanks. this does the

Brian Lian

though, when means in any you to -- the and tends tends largest when actually to Yeah, of as be dose, the observed at to at related, in you bit data higher. so little dosing. It the It be tends dose. to increase relative look XX-week the a does occur highest -- placebo think resolve everybody. interruption happen, to when Interestingly, you a the mean reduction tends dose I it early the bump it look is that it doesn't without is so

And in that you see lipid benefit this content. reduction so with robust consistent from that's a

Timur Ivannikov

Okay, our question five if Maybe I the you -- selection guess, thinking to study. decision I come study? dose in of is five is milligram new. got but you've to this whether talk pretty the data not the selection you sure whether it. in next current sure Not And know answer, Phase what include since dose final milligram then, don't of can about on could if a dose the IIb that the

Brian Lian

still some clearly that, from study additional in seen a a doses. design going achieve question. but IIa details the the not we from a clinical meaningful as I disclose the of the representation reduce We're we've upcoming can likely study and think the is say to be there little And data would what study you benefit. bit as it's will Yeah, well get I until closer, the Phase good pretty dose

we've choosing the great got next study. here for doses And in think I flexibility so, a

Timur Ivannikov

the you Thank Appreciate Okay. very much. details.

Brian Lian

Thanks. Okay.

Operator

Zacks ahead. with Research. Bautz today question Please from next David Investment Our comes go

David Bautz

Brian. good Hey, afternoon

Brian Lian

David. Hi,

David Bautz

XXXX, TR partners of are beta any potential I a been there's you partnerships? Basically about general. question lot if and having wondering, any first out I'm those if I class are think so, is, impact partnership there on disinformation the wondering XXXX, seeing in what in and have of interest The that's mean, potential

Brian Lian

Yeah.

So on safety not much I any having, safety about the would interested profile don't there parties. the from want questions to many color recognize really third potency say, and but I or too profile may be discussions we give may any and people aren’t

a there's I think comfort there. of fair amount

David Bautz

you trial, now? Okay. so And other as are patient NASH upcoming on far with many concerned right going trials how enrollment as the about

Brian Lian

very Yeah, it's a key question. concerned. We're

something those patients enroll everybody of It's interest of is all say any you that Xa industry studies and way. be be effort space. I And issues prior very think that don't would sponsors accordingly. competition certainly, just a factor try worse competitive the We a study. a that's out study there, -- it I this plan will studies, -- mitigate in lot wouldn't it's high the easier lot other We of be to for But a think would there to study the every similar. making than the though. will think knowing think enrollment. of might But a limit quite than upcoming it bit under Phase be to

David Bautz

taking questions. you appreciate the I

Brian Lian

David. Thanks,

Operator

with question Blair. comes go Please Andy from William next The Hsieh ahead.

Andy Hsieh

Hi. Thanks for congrats taking my questions the progress. on and

a done posters. I EASL on question you So that have have analysis eDISH the about the

some design some of none this, patients your interpretation FDA eDISH analysis? there the Corollary quadrant, patients it's of curious how non placebo Hy's like including were I considered guess, Temple's are quadrant So matching the -- the in patients just So -- Law,

Brian Lian

regression is Hy's Temple's plot bilirubin And ALT, to bili tends a into two population well that a a as set in continued I close quadrant indicates plot, greater you not the we did to over that's studies, We time, total and looking that Temple's consistent health. shows. Phase demonstrate only are sorry is end Interestingly, looked see at Phase it would the Corollary which reason to of looks be was a X a you left what more And patients, maximum time at And total -- any that be ALT Temple's over the study. bilirubin relative that has to something the moving when is Law. in to even the greater not transient much it's did for X this -- as Phase totally really see you that liver -- percentage treated Corollary been of there pure ALT, regress bilirubin given see the coming at it's of the and quadrant, with combination is plots. see of risk clearly in and end anybody that historical what's something eDISH I'm in interest maximum see since of that Corollary more We in which Law Hy's the in quadrant, a lower I Yeah, ALT. to quadrant which and don't not We the and harmful called interesting you're study placebo exposure didn't and the further analysis, with normal the the pop and there into actually it's that that consistent eDISH window. patients draft. very maximum improving exposure analysis. would higher quadrant, and just from a liver At with end but so think

Andy Hsieh

explanation. updated Thanks Also detailed Yes. for Great. curious [Technical Difficulty] about just that any

Brian Lian

Andy. you there, I'm sorry cut out

Andy Hsieh

me Can about Sorry, hear that. now? you

Brian Lian

hear last hear the I didn't can now. question. part the of I Yes, you

Andy Hsieh

sorry. Oh,

Okay.

last I curious in systems there's if are any potentially quarterly any on So VKXXXX. forward? you the the call, that during single-payer very about update path potential talked and was interested

Brian Lian

looking around question. in the maybe, misremembering room system I respect don't don’t the I to recall with the I'm VKXXXX. here, discussing -- payer single I'm

Andy Hsieh

not like you maybe a payer specifically in see Europe. Or or maybe in you'd Japan maybe talked single on that about payer system, maybe Japan,

Brian Lian

Yes, yes.

Sorry. Yes.

was patients the bundle in hospital flexibility result, longer to there Japanese learned payments there. Japan, study was to to relative pricing the is western for the in And So, since structure stay a period time markets. since a we interactions as numerous insurance reported the room tend hospital that what little through for

We the the research patients was more Western those to think to parties that the discharged us in – that's And only in West surprising it was to it relative surprising was hip the don't surprising the that rapidly exercises. are Japan. markets. case us. of market that but so, time Most fracture not necessarily And conducted actually, much

So don't markets. feed any Western would that into we think in decisions

are from registration a fracture, path registration that What involve we've I X and hip long difficult think the that to when but them, discussions life. is FDA a exceptionally more Phase end complete makes successfully study would each very with difficult alone. it's endpoints. problematically something is large combines trial those individually anticipated for you quality and the -- points, of And it combine without learned it to that going pursue we're not function

Andy Hsieh

Okay, answering great. my for all you Thank questions.

Brian Lian

Thanks, Andy.

Operator

next comes and question ahead. Yale Company. Laidlaw The go from Please Jen with

Yale Jen

for Good afternoon and questions. taking the thanks

presentation the you and then that You script level focus you FX bit more on mind study a elaborate maybe more mentioned with earlier fibrosis behind FX little a rationale of in the and were the FX it? Would Phase patients. Xb for and

Brian Lian

Yale. thanks Yeah,

segment the their the around overall FX, that market. to We cirrhosis are at the and failure. liver be the likely of who it's that anticipate complications with risk reimbursed a-third will of patients have the further compensated cirrhosis the Those NASH market, FX greatest progressing the liver most of population, So initially. least

be at that the And end looking so, that's of spectrum. why we'll

relative We what those and understand any groups just differences across two drug's will those. the include to FX's is understand though, patient efficacy in

And to analysis statistical stratify plan for the these efficacy so various in in populations.

Yale Jen

question quarter, the million a the this statement less make maybe that probably cash. but just probably reported a just of we curious the in -- used just just housekeeping realized for just front I cash Okay, have quarter than first what tighter -- cash you you for know in helpful. will guys flow learned And year, very guys, that maybe the $X that on the great. such we be expenses quarter? That's Qs,

Brian Lian

Yeah.

bit we balance question, this the than feels appreciate I'm that So is little like income. spend surprised offset the It budget cash interest I do and the we spending so as of more the a well. always -- some is because by -- money

realize month do provides a income, million a we and over interest So so $X.X an in offset. that

OpEx, If last it's higher think look not than I'm this XX% mistaken. the overall I you at -- if it's year year about

Yale Jen

of I you but in maybe of study projection in that I Phase And is have question year or give on being? Could will this Thanks. next that, here the overall study filing, be you the you a time probably of terms any pretty study last little the you give bit later XXXX. And complete final details how colors IND on when for probably know will overview designed. first more

Brian Lian

Yeah, thanks Yale.

a evaluate So fairly unique days. would with very here, or acid with lot study chain fatty changes multiple rolls XX component the component ascending X-ALD. and we ascending this component haven't rolls a think a level three of design. likely a XX into dose be given would in study of detail after dose could but form I into you a patients have study And of two days would long we We think most single patients the AMN of that a and dose disease that that

Yale Jen

progress. a Thanks lot great. Okay, and on the congrats

Brian Lian

you. Thank

Operator

ahead. Mayank Instructions] with Our [Operator question Please next FBR. Riley B. go Mamtani comes from

Mayank Mamtani

on congrats XXXX, I progress. couple On improved a XXX. very Thanks problem a the XXXX, and at responses and then on mean, for question on high-quality one have you of lower my having have doses. taking I

So just could study that that finding about a obviously back, do low how you've drug traditional opposite you does done taking lowest effective like like think how It's a go. development. bit step to now that you

thinking size think population in can the now that I, you haven't you you if you biopsies, patient know how do then go you Phase didn't patients about you're you comment fibrosis about that? just but of FX, the And what you into how MRI-PDFF. FX, F offered, like on framework, said, had the so status on have So you don't the FX, effect

How going thinking reduction, that. that would those before not in It you're helpful few then thinking I things on you're fat about be a of think into couple on just the have years. specifics, And a you the helpful. a histology Again, reduction, you'd understand data but would just question very brief I of XXX? measure in be have be -- how you're that to that? ALT I to looking know on some about just

Brian Lian

Yeah, thanks Mayank.

start as And of And at minimal X see you cohorts dose, that upcoming XX data, anyway. is where include effective it like looks exploration will as milligram least the activity. look we when far some at in day study around so you lower the one some dose to

across different so that, -- didn't parameters, programs we NASH that -- not study. often prove assume severity, When this it there's have down data, incorrect But we that delivered NASH similar look period, wise there since was this exercise. drug you The I FDA always not severities. there be other We show think nice data the because sense in so, coming below With seems to minimally targeted NASH study. longer may are, we at misconstrued to XX over from fat, biopsy. see and patients -- respect that a show efficacy is it's based on have wants that the to in the Xx across the really allowed a at you effective F, think seem Xx, targeted down essentially see liver significant to were going milligram patients I understand study. XXx. to makes were And a think in not where But day a to doses I and I a efficacy so think X Absolutely, representation might identical see a so metabolic the of we might effect something cannot and there. given baseline

we severity, seems point. should at but And that so, this demonstrate show look at And the lipids what out, look data other have a this efficacy of you you increase plasma as it find not that we at certainly think fat, impact. certainly on that that does and benefits if measures in know shows if you but seem to mechanism liver baseline major we'll to

and see So, FX. necessarily effect it's why it's if there's be an on not would it there hard hard see FX to fibrosis, -- to why with

So, good sense, question. I but makes hope that

Mayank Mamtani

ask follow-up NASH itself. That can does and a if maybe on I

combinations. a you pursuing you histology? do the II from you to point into So or that intend the getting do at point while do more you obviously while Phase the bigger seeing to Like, you through ones, especially on do have do go -- your maybe we're some at that time future Phase II and data maybe once, stage, partnering companies, intend

Brian Lian

question. There's combinations. of it's a good lot in interest Yeah, a

I explore well certainly party. want combinations. to that and conversations other that minded be Viking sense to would for have think opened to flexible They and and we forward move we're would allow be arrangements as as receptive to make us the would

to need individually. those we to next thinking so, combinations. arise, complete evaluate don't we And certainly, as begin the will about study them But

Mayank Mamtani

partnering shows is is great, at and there then of correlation outcome you're happened very already briefly a looked work functional That or Again, is not XXX, has Sounds natural institute with some being that lot long with assets work at disease as I the understand maybe population? is with. fatty maybe chain this reference point. of a any in progress on that history study published this

Brian Lian

population seems those to know population. reduce diseases. animals, translate have are one there often the in AMN it phenotype. the the so studies. and fatty chain get studies of a inflammatory the challenges ALD studies. signaling. until to actually get with very it ability really But of in on onset just good chain yeah, humans the long to human handle it's natural of do you that with Yeah, the assets into long been It's you delay orphan seems part And correlations hard We not very to reduce when The of acids, the fatty history

really of that's data of great reflection there. it's So a just the but not a answer, lack

Mayank Mamtani

Thank questions. my great. for taking sounds you Okay,

Brian Lian

Mayank. Thanks

Operator

concludes Stephanie for remarks. closing like to back turn Diaz over question-and-answer session. to any would This conference I the our

Stephanie Diaz

participation again updating Therapeutics. of to your Viking for again forward you look coming the We Have support continued you a and great afternoon. Thank in months.

You can now. all disconnect Thanks.

Operator

you now presentation. Thank conference concluded. attending The is today's for

Viking Therapeutics (VKTX) 2 May 192019 Q1 Earnings call transcript